| 引用本文: |
崔林阁,杨晓波,刘畅,梁武,王先洁.健肝化纤胶囊联合恩替卡韦治疗脾虚血瘀型慢性乙型肝炎肝纤维化疗效观察[J].湖南中医药大学学报,2020,40(12):1553-1556[点击复制] |
|
| |
|
|
| 本文已被：浏览 1945次 下载 1099次 |
| 健肝化纤胶囊联合恩替卡韦治疗脾虚血瘀型慢性乙型肝炎肝纤维化疗效观察 |
| 崔林阁,杨晓波,刘畅,梁武,王先洁 |
| (溆浦县中医医院肝病科, 湖南 溆浦 419300;湖南中医药大学, 湖南 长沙 410208) |
| 摘要: |
| 目的 观察健肝化纤胶囊联合恩替卡韦对脾虚血瘀型慢性乙型肝炎肝纤维化患者乙肝病毒脱氧核糖核酸（hepatitis b virus DNA，HBV-DNA）转阴率、血清谷草转氨酶（aspartate aminotransferase，AST）、谷丙转氨酶（alanine aminotransferase，ALT）及肝纤维化指标的影响。方法 将80例脾虚血瘀型慢性乙型肝炎肝纤维化患者随机分为治疗组40例和对照组40例，两组患者均常规给予恩替卡韦治疗，治疗组加用健肝化纤胶囊，疗程为6个月。观察两组治疗前后HBV-DNA、ALT、AST及肝纤维化指标的变化。结果 治疗后治疗组HBV-DNA阴转率（92.5%）与对照组（90.0%）相比差异无统计学意义（P>0.05）；两组ALT、AST较治疗前均明显下降（P<0.05），两组间比较差异无统计学意义（P>0.05）；对照组治疗后肝纤维化改善不明显（P>0.05），治疗组肝纤维化指标较治疗前明显下降（P<0.05），优于对照组（P<0.05）。结论 健肝化纤胶囊联合恩替卡韦可改善脾虚血瘀型慢性乙型肝炎肝纤维化患者肝纤维化程度。 |
| 关键词: 慢性乙型肝炎肝纤维化 脾虚血瘀 健肝化纤胶囊 恩替卡韦 |
| DOI：10.3969/j.issn.1674-070X.2020.12.022 |
| 投稿时间：2020-06-01 |
| 基金项目:湖南省中医药科研计划项目（201950）。 |
|
| Efficacy Observation on Jian'gan Huaxian Capsule Combined with Entecavir in the Treatment of Liver Fibrosis of Chronic Hepatitis B with Spleen Deficiency and Blood Stasis Syndrome |
| CUI Linge,YANG Xiaobo,LIU Chang,LIANG Wu,WANG Xianjie |
| (Xupu Hospital of Traditional Chinese Medicine, Xupu, Hunan 419300, China;Hunan University of Chinese Medicine, Changsha, Hunan 410208, China) |
| Abstract: |
| Objective To observe the effects of Jian'gan Huaxian Capsule combined with entecavir on hepatitis B virus DNA (HBV-DNA) negative conversion rate, serum aspartate aminotransferase (AST), alanine aminotransferase (ALT) and liver fibrosis indexes in patients with chronic hepatitis B liver fibrosis of spleen deficiency and blood stasis syndrome. Methods A total of 80 cases of chronic hepatitis B with liver fibrosis of spleen deficiency and blood stasis syndrome were randomly assigned into a treatment group (n=40) and a control group (n=40). Both groups were treated with entecavir as routine, while the treatment group was additionally treated with Jian'gan Huaxian capsule. The course of treatment was 6 months. The changes of HBV-DNA, ALT, AST and liver fibrosis indexes were observed and compared between the 2 groups before and after treatment. Results After the treatment, the HBV-DNA negative conversion rate (92.5%) of the treatment group was not significantly different from that of the control group (90.0%) (P>0.05); the ALT and AST of the 2 groups were significantly decreased than before the treatment (P<0.05), but the difference between the 2 groups was not statistically significant (P>0.05); the improvement of liver fibrosis in the control group was not significant after the treatment (P>0.05), and the liver fibrosis indexes in the treatment group were significantly decreased than before the treatment (P<0.05), and it was better than the control group (P<0.05). Conclusion Jian'gan Huaxian Capsule combined with entecavir can improve the degree of liver fibrosis in patients with chronic hepatitis B with spleen deficiency and blood stasis syndrome. |
| Key words: chronic hepatitis B liver fibrosis spleen deficiency and blood stasis Jian'gan Huaxian Capsule Entecavir |
|
二维码（扫一下试试看！） |
|
|
|
|
